NASDAQ:ADAG Adagene (ADAG) Stock Forecast, Price & News $1.32 0.00 (0.00%) (As of 03:58 PM ET) Add Compare Share Share Today's Range$1.31▼$1.3550-Day Range$1.29▼$1.5452-Week Range$0.90▼$2.88Volume4,205 shsAverage Volume18,409 shsMarket Capitalization$57.09 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 ProfileProfileAnalyst RatingsChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Adagene MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside273.1% Upside$5.00 Price TargetShort InterestHealthy0.05% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.37Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.92) to ($2.05) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.03 out of 5 starsMedical Sector618th out of 1,006 stocksPharmaceutical Preparations Industry305th out of 492 stocks 3.5 Analyst's Opinion Consensus RatingAdagene has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.00, Adagene has a forecasted upside of 273.1% from its current price of $1.34.Amount of Analyst CoverageAdagene has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.05% of the float of Adagene has been sold short.Short Interest Ratio / Days to CoverAdagene has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Adagene has recently increased by 108.51%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAdagene does not currently pay a dividend.Dividend GrowthAdagene does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ADAG. Previous Next 1.9 News and Social Media Coverage News SentimentAdagene has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Adagene this week, compared to 1 article on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Adagene insiders have not sold or bought any company stock.Percentage Held by Insiders21.20% of the stock of Adagene is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 13.68% of the stock of Adagene is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Adagene are expected to decrease in the coming year, from ($1.92) to ($2.05) per share.Price to Book Value per Share RatioAdagene has a P/B Ratio of 0.70. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Adagene (NASDAQ:ADAG) StockAdagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.Read More Receive ADAG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adagene and its competitors with MarketBeat's FREE daily newsletter. Email Address ADAG Stock News HeadlinesMay 28, 2023 | americanbankingnews.comShort Interest in Adagene Inc. (NASDAQ:ADAG) Grows By 108.5%May 25, 2023 | finance.yahoo.comIs Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?May 31, 2023 | Edge On The Street (Ad)Soaring EV Industry Keeps Investor Focus on LithiumThe need for lithium keeps going up, up, up with the mass adoption of electric vehicles. The lithium demand for EV batteries alone is now double the rate of lithium production.May 23, 2023 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Poseida Therapeutics (PSTX), Mustang Bio (MBIO)May 16, 2023 | americanbankingnews.comAdagene Inc. (NASDAQ:ADAG) Sees Large Decrease in Short InterestMay 4, 2023 | finance.yahoo.comAdagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second SAFEbody® Novel Masked Antibody-Drug ConjugateApril 30, 2023 | americanbankingnews.comAdagene Inc. (NASDAQ:ADAG) Short Interest Down 28.8% in AprilApril 28, 2023 | finance.yahoo.comAdagene Announces Updates to its Board of DirectorsMay 31, 2023 | Edge On The Street (Ad)Soaring EV Industry Keeps Investor Focus on LithiumThe need for lithium keeps going up, up, up with the mass adoption of electric vehicles. The lithium demand for EV batteries alone is now double the rate of lithium production.April 24, 2023 | americanbankingnews.comAdagene (NASDAQ:ADAG) Given Buy Rating at HC WainwrightApril 24, 2023 | americanbankingnews.comAdagene's (ADAG) Buy Rating Reiterated at HC WainwrightApril 22, 2023 | msn.comHC Wainwright & Co. Reiterates Adagene Inc - ADR (ADAG) Buy RecommendationApril 21, 2023 | markets.businessinsider.comExpert Ratings for AdageneApril 18, 2023 | finance.yahoo.comAdagene Presents Clinical Data for Anti-CTLA-4 SAFEbody® ADG126 Reinforcing Best-in-Class Safety Profile at Repeat Doses and Showing Early Efficacy Profile in Advanced/Metastatic Solid TumorsApril 18, 2023 | americanbankingnews.comAdagene Inc. (NASDAQ:ADAG) Sees Large Increase in Short InterestApril 1, 2023 | americanbankingnews.comAdagene Inc. (NASDAQ:ADAG) Sees Significant Increase in Short InterestMarch 31, 2023 | msn.comAre Medical Stocks Lagging Adagene (ADAG) This Year?March 31, 2023 | finance.yahoo.comAre Medical Stocks Lagging Adagene (ADAG) This Year?March 31, 2023 | finance.yahoo.comAdagene Full Year 2022 Earnings: US$1.85 loss per share (vs US$1.83 loss in FY 2021)March 31, 2023 | americanbankingnews.comAdagene Inc. (NASDAQ:ADAG) to Post FY2023 Earnings of ($1.49) Per Share, HC Wainwright ForecastsMarch 31, 2023 | americanbankingnews.comHC Wainwright Reiterates "Buy" Rating for Adagene (NASDAQ:ADAG)March 29, 2023 | finanznachrichten.deAdagene Inc.: Adagene Reports Full Year 2022 Financial Results and Provides Corporate UpdateMarch 28, 2023 | finance.yahoo.comAdagene Reports Full Year 2022 Financial Results and Provides Corporate UpdateMarch 21, 2023 | americanbankingnews.comAdagene (NASDAQ:ADAG) Receives Buy Rating from HC WainwrightMarch 21, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Its Buy Rating for Adagene (ADAG)March 16, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Hookipa Pharma (HOOK)March 14, 2023 | finance.yahoo.comAdagene Announces Poster Presentations on Anti-CTLA-4 SAFEbody®, ADG126, at Upcoming American Association for Cancer Research (AACR) Annual Meeting in AprilSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ADAG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adagene and its competitors with MarketBeat's FREE daily newsletter. Email Address ADAG Company Calendar Today5/31/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ADAG CUSIPN/A CIK1818838 Webwww.adagene.com Phone86-512-8777-3632FaxN/AEmployees198Year FoundedN/APrice Target and Rating Average Stock Price Forecast$5.00 High Stock Price Forecast$5.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+274.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.17 Current Ratio2.71 Quick Ratio2.71 Sales & Book Value Annual Sales$9.29 million Price / Sales6.22 Cash FlowN/A Price / Cash FlowN/A Book Value$1.91 per share Price / Book0.70Miscellaneous Outstanding Shares43,250,000Free Float34,083,000Market Cap$57.74 million OptionableNot Optionable Beta0.05 Key ExecutivesDr. Peter P. Luo Ph.D. (Age 56)Co-Founder, CEO & Chairman Mr. Man Kin Tam M.B.A. (Age 45)CFO & Director Dr. Fangyong Du Ph.D. (Age 52)Chief Technology Officer Dr. Jc Xu M.D. (Age 57)Ph.D., Chief Scientific Officer Ms. Ami Celeste KnoeflerVP of Investor Relations & Corp. CommunicationsMs. Ling ZhouHead of HRDr. Qinghai Zhao (Age 61)Chief Manufacturing Officer Ms. Yan Li M.B.A. (Age 47)Sr. VP of Bioinformatics & Information Technology Ms. Xiaohong She (Age 55)Sr. VP & Head of Clinical Operations Dr. Guizhong Liu Ph.D. (Age 51)Head of Biology & Pharmacology More ExecutivesKey CompetitorsGain TherapeuticsNASDAQ:GANXAbeona TherapeuticsNASDAQ:ABEOHomology MedicinesNASDAQ:FIXXLifeVantageNASDAQ:LFVNGalectoNASDAQ:GLTOView All CompetitorsInstitutional OwnershipRenaissance Technologies LLCSold 34,959 shares on 5/12/2023Ownership: 0.092%Strategic Vision Investment LtdSold 10,400 shares on 5/10/2023Ownership: 0.813%View All Institutional Transactions ADAG Stock - Frequently Asked Questions Should I buy or sell Adagene stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adagene in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ADAG shares. View ADAG analyst ratings or view top-rated stocks. What is Adagene's stock price forecast for 2023? 2 analysts have issued 12-month target prices for Adagene's stock. Their ADAG share price forecasts range from $5.00 to $5.00. On average, they anticipate the company's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 274.5% from the stock's current price. View analysts price targets for ADAG or view top-rated stocks among Wall Street analysts. How have ADAG shares performed in 2023? Adagene's stock was trading at $1.3250 at the beginning of the year. Since then, ADAG shares have increased by 0.8% and is now trading at $1.3350. View the best growth stocks for 2023 here. Are investors shorting Adagene? Adagene saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 19,600 shares, an increase of 108.5% from the April 30th total of 9,400 shares. Based on an average daily trading volume, of 10,700 shares, the short-interest ratio is currently 1.8 days. Currently, 0.1% of the shares of the company are short sold. View Adagene's Short Interest. When did Adagene IPO? (ADAG) raised $133 million in an initial public offering on Tuesday, February 9th 2021. The company issued 7,400,000 shares at $17.00-$19.00 per share. Goldman Sachs (Asia), Morgan Stanley and Jefferies served as the underwriters for the IPO and China Renaissance was co-manager. What is Adagene's stock symbol? Adagene trades on the NASDAQ under the ticker symbol "ADAG." Who are Adagene's major shareholders? Adagene's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Strategic Vision Investment Ltd (0.81%) and Renaissance Technologies LLC (0.09%). How do I buy shares of Adagene? Shares of ADAG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Adagene's stock price today? One share of ADAG stock can currently be purchased for approximately $1.34. How much money does Adagene make? Adagene (NASDAQ:ADAG) has a market capitalization of $57.74 million and generates $9.29 million in revenue each year. How many employees does Adagene have? The company employs 198 workers across the globe. How can I contact Adagene? Adagene's mailing address is 4F BUILDING C14 NO. 218 XINGHU STREET SUZHOU INDUSTRIAL PARK, JIANGSU F4, 215123. The official website for the company is www.adagene.com. The company can be reached via phone at 86-512-8777-3632 or via email at ir@adagene.com. This page (NASDAQ:ADAG) was last updated on 5/31/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adagene Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.